Home > Insider Trading > Filing (0001209191-21-037475)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1557746	Aclaris Therapeutics Inc.	ACRS	Pharmaceutical Preparations (2834)	460571712

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1654450	Frank Ruffo	C/O Aclaris Therapeutics, Inc. 640 Lee Road, Suite 200 Wayne PA 19087	Chief Financial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-06-01	33,189	$0.00	184,909	No	4	M	Direct
Common Stock	Disposition	2021-06-02	12,587	$21.51	172,322	No	4	S	Direct
Common Stock	Disposition	2021-06-02	2,450	$22.30	169,872	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Units	Disposition	2021-06-01	33,189	$0.00	33,189	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	M	Direct

Footnotes

Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on June 1, 2021 pursuant to preexisting sell-to-cover elections.
The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.06 to $22.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.06 to $22.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares underlying these restricted stock units vested in two equal annual installments beginning on June 1, 2020.